

Binghe Xu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1626898/publications.pdf>

Version: 2024-02-01

179
papers

6,726
citations

172457

29
h-index

74163

75
g-index

185
all docs

185
docs citations

185
times ranked

8749
citing authors

#	ARTICLE	IF	CITATIONS
1	Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 523-533.	27.0	2,256
2	Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 580-591.	10.7	434
3	Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. <i>Cancer Cell</i> , 2021, 39, 1578-1593.e8.	16.8	275
4	Targeted therapeutic options and future perspectives for HER2-positive breast cancer. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 34.	17.1	242
5	Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2610-2619.	1.6	226
6	Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 351-360.	10.7	188
7	Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor -Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3105-3112.	1.6	168
8	Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 1296-1304.	7.0	146
9	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 357-366.	10.7	125
10	Enriched CD44+/CD24- population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). <i>Cancer Letters</i> , 2014, 353, 153-159.	7.2	113
11	Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. <i>British Journal of Cancer</i> , 2018, 119, 538-545.	6.4	111
12	The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. <i>Cancer Communications</i> , 2019, 39, 1-10.	9.2	86
13	ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. <i>Oncotarget</i> , 2016, 7, 66020-66031.	1.8	75
14	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. <i>European Journal of Cancer</i> , 2019, 120, 20-30.	2.8	75
15	Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel. <i>PLoS ONE</i> , 2014, 9, e104870.	2.5	66
16	Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. <i>Nature Medicine</i> , 2021, 27, 1904-1909.	30.7	65
17	Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial. <i>Oncotarget</i> , 2016, 7, 60647-60656.	1.8	63
18	Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 5212-5220.	7.0	60

#	ARTICLE	IF	CITATIONS
19	Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. <i>European Journal of Cancer</i> , 2019, 112, 57-65.	2.8	56
20	MicroRNA-21 Identified as Predictor of Cancer Outcome: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e103373.	2.5	55
21	Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China. <i>Cancer</i> , 2019, 125, 742-749.	4.1	55
22	Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. <i>International Journal of Cancer</i> , 2020, 146, 1359-1368.	5.1	55
23	RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies. <i>Journal of Clinical Oncology</i> , 2021, 39, 1022-1022.	1.6	48
24	Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer. <i>Cancer Medicine</i> , 2018, 7, 4420-4433.	2.8	46
25	In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China. <i>Frontiers in Oncology</i> , 2021, 11, 774577.	2.8	46
26	The emerging role of hypoxia-inducible factor-2 involved in chemo/radioresistance in solid tumors. <i>Cancer Treatment Reviews</i> , 2015, 41, 623-633.	7.7	44
27	Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. <i>Lancet Oncology</i> , The, 2017, 18, 371-383.	10.7	43
28	The Demographic Features, Clinicopathological Characteristics and Cancer-specific Outcomes for Patients with Microinvasive Breast Cancer: A SEER Database Analysis. <i>Scientific Reports</i> , 2017, 7, 42045.	3.3	41
29	Current management of chemotherapy-induced neutropenia in adults: key points and new challenges. <i>Cancer Biology and Medicine</i> , 2020, 17, 896-909.	3.0	35
30	A CLDN1-Negative Phenotype Predicts Poor Prognosis in Triple-Negative Breast Cancer. <i>PLoS ONE</i> , 2014, 9, e112765.	2.5	33
31	Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody. <i>Thoracic Cancer</i> , 2019, 10, 1395-1401.	1.9	33
32	Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 59.	5.2	32
33	Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage. <i>Frontiers in Oncology</i> , 2020, 10, 902.	2.8	28
34	Age-Related Disparity in Immediate Prognosis of Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer Registries. <i>PLoS ONE</i> , 2015, 10, e0128345.	2.5	27
35	Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. <i>BMC Cancer</i> , 2019, 19, 442.	2.6	26
36	Clinicopathological characteristics and prognosis of breast cancer with special histological types: A surveillance, epidemiology, and end results database analysis. <i>Breast</i> , 2020, 54, 114-120.	2.2	26

#	ARTICLE	IF	CITATIONS
37	Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis. <i>Scientific Reports</i> , 2017, 7, 5995.	3.3	25
38	The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population. <i>International Journal of Cancer</i> , 2018, 143, 184-189.	5.1	25
39	Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 689-697.	2.5	25
40	Fulvestrant 250Âmg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 223-230.	2.3	24
41	Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 67-77.	2.5	24
42	Management of Contralateral Axillary Lymph Node Metastasis from Breast Cancer: A Clinical Dilemma. <i>Tumori</i> , 2014, 100, 600-604.	1.1	23
43	Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression. <i>Cancer Letters</i> , 2021, 523, 43-56.	7.2	23
44	The emerging role of RNA N6-methyladenosine methylation in breast cancer. <i>Biomarker Research</i> , 2021, 9, 39.	6.8	22
45	Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes. <i>Cancer Medicine</i> , 2019, 8, 2074-2084.	2.8	21
46	Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial. <i>BioDrugs</i> , 2021, 35, 337-350.	4.6	21
47	Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. <i>Scientific Reports</i> , 2020, 10, 8753.	3.3	20
48	Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1003-1003.	1.6	20
49	Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial. <i>Oncotarget</i> , 2015, 6, 18683-18692.	1.8	20
50	Biweekly gemcitabineâ€“paclitaxel, gemcitabineâ€“carboplatin, or gemcitabineâ€“cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. <i>Breast Cancer</i> , 2011, 18, 203-212.	2.9	19
51	Phase II trial of utidalone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients. <i>Journal of Hematology and Oncology</i> , 2016, 9, 68.	17.0	19
52	Cardia and Non-Cardia Gastric Cancer Have Similar Stage-for-Stage Prognoses After R0 Resection: a Large-Scale, Multicenter Study in China. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 700-707.	1.7	19
53	Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1. <i>Breast Cancer Research</i> , 2017, 19, 47.	5.0	19
54	Polymorphisms in AURKA and AURKB are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy. <i>Cancer Management and Research</i> , 2018, Volume 10, 3801-3808.	1.9	19

#	ARTICLE	IF	CITATIONS
55	The molecular tumor burden index as a response evaluation criterion in breast cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 251.	17.1	19
56	An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1028-1028.	1.6	19
57	Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells. <i>Oncotarget</i> , 2016, 7, 65993-66002.	1.8	19
58	Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China. <i>Cancer Communications</i> , 2020, 40, 260-269.	9.2	18
59	The Landscape of Cell and Gene Therapies for Solid Tumors. <i>Cancer Cell</i> , 2021, 39, 7-8.	16.8	18
60	Irinotecan plus S1 versus S1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-label phase 3 trial. <i>Cancer Communications</i> , 2019, 39, 1-10.	9.2	17
61	Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer. <i>Cancer Biology and Medicine</i> , 2021, 18, 849-859.	3.0	17
62	Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience. <i>Oncotarget</i> , 2016, 7, 33391-33407.	1.8	17
63	Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors. <i>Anticancer Research</i> , 2016, 36, 6185-6194.	1.1	17
64	The Significance and Therapeutic Potential of GATA3 Expression and Mutation in Breast Cancer: A Systematic Review. <i>Medicinal Research Reviews</i> , 2015, 35, 1300-1315.	10.5	16
65	The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study. <i>Cancer Communications</i> , 2018, 38, 1-11.	9.2	16
66	Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study. <i>Oncology Letters</i> , 2019, 17, 4768-4778.	1.8	16
67	Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology. <i>Cancer Biology and Medicine</i> , 2019, 16, 189.	3.0	16
68	Progress in systemic therapy for triple-negative breast cancer. <i>Frontiers of Medicine</i> , 2021, 15, 1-10.	3.4	16
69	Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study. <i>PLoS ONE</i> , 2015, 10, e0136268.	2.5	15
70	Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: Phase 3 randomized trial. <i>Cancer</i> , 2015, 121, 3412-3421.	4.1	15
71	Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China. <i>Oncotarget</i> , 2016, 7, 57301-57309.	1.8	15
72	Young breast cancer patients who develop distant metastasis after surgery have better survival outcomes compared with elderly counterparts. <i>Oncotarget</i> , 2017, 8, 44851-44859.	1.8	15

#	ARTICLE	IF	CITATIONS
73	Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018). <i>Cancer</i> , 2020, 126, 3867-3882.	4.1	15
74	Primary Tumor Surgery for Patients with De Novo Stage IV Breast Cancer can Decrease Local Symptoms and Improve Quality of Life. <i>Annals of Surgical Oncology</i> , 2020, 27, 1025-1033.	1.5	15
75	Neuroendocrine carcinoma of the breast: a review of 126 cases in China. <i>Chinese Journal of Cancer</i> , 2017, 36, 45.	4.9	14
76	<p>Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4699-4706.	1.9	14
77	A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer. <i>Biomarker Research</i> , 2021, 9, 24.	6.8	14
78	National consensus in China on diagnosis and treatment of patients with advanced breast cancer. <i>Annals of Translational Medicine</i> , 2015, 3, 242.	1.7	14
79	Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 323.	2.5	14
80	Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy. <i>Chinese Journal of Cancer</i> , 2018, 37, 4.	4.9	13
81	Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer. <i>Biomarker Research</i> , 2021, 9, 28.	6.8	13
82	A single-nucleotide polymorphism in the 3' UTR region of the adipocyte fatty acid binding protein 4 gene is associated with prognosis of triple-negative breast cancer. <i>Oncotarget</i> , 2016, 7, 18984-18998.	1.8	13
83	Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 535-544.	2.5	12
84	Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China. <i>International Journal of Cancer</i> , 2018, 143, 2499-2504.	5.1	12
85	Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers. <i>Breast</i> , 2020, 52, 17-22.	2.2	12
86	Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer. <i>Cancer Medicine</i> , 2021, 10, 109-118.	2.8	12
87	Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092599.	3.2	11
88	Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China. <i>International Journal of Cancer</i> , 2020, 147, 3490-3499.	5.1	11
89	DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis. <i>Annals of Translational Medicine</i> , 2021, 9, 220-220.	1.7	11
90	A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 565384.	2.8	11

#	ARTICLE	IF	CITATIONS
91	Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis. <i>Current Problems in Cancer</i> , 2020, 44, 100606.	2.0	11
92	Prognostic Model and Nomogram for Estimating Survival of Small Breast Cancer: A SEER-based Analysis. <i>Clinical Breast Cancer</i> , 2021, 21, e497-e505.	2.4	10
93	An open-label, dose-escalation phase I study to evaluate RC48-ADC, a novel antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1030-1030.	1.6	10
94	Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study. <i>Oncotarget</i> , 2016, 7, 50643-50655.	1.8	10
95	Efficacy and safety of duloxetine in Chinese breast cancer patients with paclitaxel-induced peripheral neuropathy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2017, 29, 411-418.	2.2	9
96	Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 602222.	2.8	9
97	Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103376.	4.4	9
98	Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 759-770.	2.2	9
99	Genome-wide chromosomal instability by cell-free DNA sequencing predicts survival in patients with metastatic breast cancer. <i>Breast</i> , 2020, 53, 111-118.	2.2	8
100	Clinical features and prognostic factors for extracranial oligometastatic breast cancer in China. <i>International Journal of Cancer</i> , 2020, 147, 3199-3205.	5.1	8
101	Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 131-141.	2.3	8
102	Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15572-e15572.	1.6	8
103	Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 485-496.	2.2	8
104	The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study. <i>International Journal of Clinical Oncology</i> , 2022, 27, 707-716.	2.2	8
105	Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER2-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients. <i>Cancer Medicine</i> , 2022, , .	2.8	8
106	Association between Lymph Node Ratio and Disease Specific Survival in Breast Cancer Patients with One or Two Positive Lymph Nodes Stratified by Different Local Treatment Modalities. <i>PLoS ONE</i> , 2015, 10, e0138908.	2.5	7
107	Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years. <i>Clinical Breast Cancer</i> , 2018, 18, e1353-e1360.	2.4	7
108	ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 571517.	2.8	7

#	ARTICLE	IF	CITATIONS
109	Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA. <i>Cancer Biology and Medicine</i> , 2021, 18, 875-887.	3.0	7
110	Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1002-1002.	1.6	7
111	Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer. <i>Journal of Cancer</i> , 2021, 12, 936-945.	2.5	6
112	Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer. <i>Targeted Oncology</i> , 2021, 16, 591-599.	3.6	6
113	A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple-negative breast cancer patients with high-recurrence risk.. <i>Journal of Clinical Oncology</i> , 2019, 37, 528-528.	1.6	6
114	Validity of distress thermometer for screening of anxiety and depression in family caregivers of Chinese breast cancer patients receiving postoperative chemotherapy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 476-484.	2.2	6
115	Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 97-105.	2.5	6
116	Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: A prospective cohort study with propensity-matched analysis. <i>International Journal of Cancer</i> , 2022, 151, 578-589.	5.1	6
117	Consistent efficacy and safety of gemcitabine-paclitaxel in patients with metastatic breast cancer: A retrospective comparison of East Asian and global studies. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 330-339.	1.1	5
118	Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nationwide multicenter study. <i>Cancer Medicine</i> , 2021, 10, 6744-6761.	2.8	5
119	Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 381-392.	2.5	5
120	Current clinical trials on breast cancer in China: A systematic literature review. <i>Cancer</i> , 2020, 126, 3811-3818.	4.1	4
121	Assessment of racial differences in the incidence of thrombocytopenia induced by trastuzumab emtansine: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2021, 9, 1139-1139.	1.7	4
122	Impact of HER2 mutation status on personalized molecular targeted therapy in advanced breast cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1039-1039.	1.6	4
123	In Reply. <i>Oncologist</i> , 2015, 20, 88-88.	3.7	3
124	Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer. <i>Oncotarget</i> , 2017, 8, 36750-36760.	1.8	3
125	The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China. <i>Clinical Breast Cancer</i> , 2019, 19, e370-e375.	2.4	3
126	Ganglioside Monosialic Acid Alleviates Peripheral Neuropathy Induced by Utidelone Plus Capecitabine in Metastatic Breast Cancer From a Phase III Clinical Trial. <i>Frontiers in Oncology</i> , 2020, 10, 524223.	2.8	3

#	ARTICLE	IF	CITATIONS
127	Mutational characteristics determined using circulating tumor DNA analysis in triple-negative breast cancer patients with distant metastasis. <i>Cancer Communications</i> , 2020, 40, 738-742.	9.2	3
128	Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 135-150.	1.8	3
129	Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy. <i>BMC Cancer</i> , 2021, 21, 341.	2.6	3
130	EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician's choice (TPC) in OlympiAD.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1045-1045.	1.6	3
131	Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China: A pooled retrospective analysis of four observational studies. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2018, 30, 327-339.	2.2	3
132	Clinicopathological Characteristics and Prognosis of Squamous Cell Carcinoma of the Breast: A Population-Based Analysis. <i>Cancer Control</i> , 2021, 28, 107327482110443.	1.8	3
133	HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials. <i>Annals of Translational Medicine</i> , 2020, 8, 1634-1634.	1.7	3
134	Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China. <i>Breast</i> , 2022, 61, 129-135.	2.2	3
135	Time to raise the bar: Transition rate of phase 1 programs on anticancer drugs. <i>Cancer Cell</i> , 2022, 40, 233-235.	16.8	3
136	Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population-based analysis. <i>Cancer Medicine</i> , 0, , .	2.8	3
137	Neratinib-based therapy in patients with metastatic HER2-positive breast cancer from Asia. <i>Future Oncology</i> , 2019, 15, 3243-3253.	2.4	2
138	Primary Trastuzumab Resistance After (Neo)adjuvant Trastuzumab-containing Treatment for Patients With HER2-positive Breast Cancer in Real-world Practice. <i>Clinical Breast Cancer</i> , 2021, 21, 191-198.	2.4	2
139	Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China. <i>Frontiers in Oncology</i> , 2020, 10, 599604.	2.8	2
140	Tumor Microenvironment Subtypes and Immune-Related Signatures for the Prognosis of Breast Cancer. <i>BioMed Research International</i> , 2021, 2021, 1-12.	1.9	2
141	Integrative clinical genomics of early-onset breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1541-1541.	1.6	2
142	Phase I safety and pharmacokinetic study of cipatinib, an original dual tyrosine kinase inhibitor. <i>Thoracic Cancer</i> , 2018, 9, 1041-1047.	1.9	1
143	Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	1.3	1
144	Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis. <i>Annals of Translational Medicine</i> , 2021, 9, 109-109.	1.7	1

#	ARTICLE	IF	CITATIONS
145	Sex-Based Heterogeneity in the Clinicopathological Characteristics and Prognosis of Breast Cancer: A Population-Based Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 642450.	2.8	1
146	Assessment of ethnic difference in the incidence of thrombocytopenia induced by trastuzumab emtansine (T-DM1): A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15096-e15096.	1.6	1
147	The intra-tumor heterogeneity of ER and HER2 expression in patients with ER-positive and HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e12550-e12550.	1.6	1
148	A real-world retrospective study of apatinib plus chemotherapy in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12507-e12507.	1.6	1
149	A phase I study of SHR6390, a cyclin-dependent kinase 4/6 inhibitor in patients with advanced breast cancer (ABC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1095-1095.	1.6	1
150	Impact of High Altitude on Clinicopathological Features and Prognosis after R0 Resection for Gastric Cancer: A Population-Based Multicenter Study. <i>Journal of Environmental Pathology, Toxicology and Oncology</i> , 2017, 36, 1-14.	1.2	1
151	Retrospective literature review of primary neuroendocrine neoplasms of the breast (BNEN) in 209 Chinese patients: Treatment and prognostic factor analysis. <i>Breast</i> , 2022, 62, 93-102.	2.2	1
152	Pyrotinib monotherapy or pyrotinib in combination with capecitabine could significantly prolong progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1034-1034.	1.6	1
153	A phase 3, randomized, open-label study of the anti-Globo H vaccine adagloxad simolenin/obi-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS611-TPS611.	1.6	1
154	First-in-human, phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3013-3013.	1.6	1
155	The clinical course and treatment results of lung metastases from breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 1998, 10, 297-300.	2.2	0
156	Timing of paclitaxel treatment in preoperative or postoperative does not affect survival in breast cancer patients. <i>Thoracic Cancer</i> , 2017, 8, 246-250.	1.9	0
157	Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer. <i>Thoracic Cancer</i> , 2018, 9, 613-620.	1.9	0
158	Discrepancies in Genetic Testing Procedures of BRCA1/2 Mutations: A National Survey Across China. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 715-721.	3.8	0
159	Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e12586-e12586.	1.6	0
160	Endocrine therapy-based strategies with different endocrine sensitivity statuses for hormone receptor positive/HER2 negative metastatic breast cancer: A network meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1062-1062.	1.6	0
161	Phase II study of apatinib plus vinorelbine, a novel combination of all-oral regimen in heavily pretreated patients with metastatic HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1123-TPS1123.	1.6	0
162	Landscape of somatic mutations in different subtypes: Advanced breast cancer with circulating tumour DNA analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23039-e23039.	1.6	0

#	ARTICLE	IF	CITATIONS
163	Phase III multicenter, randomized study of utidelone plus capecitabine versus capecitabine alone for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer.. Journal of Clinical Oncology, 2018, 36, 1003-1003.	1.6	0
164	Apatinib plus vinorelbine: A novel combination of all-oral regimen in heavily pretreated patients with metastatic HER2-negative breast cancer.. Journal of Clinical Oncology, 2018, 36, e13096-e13096.	1.6	0
165	Progression-free survival as a predictor of overall survival in patients with advanced breast cancer: A real-world study from the China National Cancer Center.. Journal of Clinical Oncology, 2019, 37, e12590-e12590.	1.6	0
166	Progression-free survival as a predictor of overall survival in patients with advanced breast cancer: A real-world study from the China National Cancer Center and validation in the Memorial Sloan Kettering Cancer Center Cohort.. Journal of Global Oncology, 2019, 5, 88-88.	0.5	0
167	The landscape of treatment and overall survival analysis of elderly patients with advanced breast cancer in China National Cancer Center.. Journal of Global Oncology, 2019, 5, 137-137.	0.5	0
168	Abstract P1-16-06: In real world, a high percentage of premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer receive chemotherapy as first-line treatment: A study of the National Cancer Center, China. Cancer Research, 2022, 82, P1-16-06-P1-16-06.	0.9	0
169	Abstract P1-08-12: The status of homologous recombination deficiency is a potential biomarker for platinum-based chemotherapy in triple-negative breast cancer. Cancer Research, 2022, 82, P1-08-12-P1-08-12.	0.9	0
170	Abstract P1-16-02: A randomized phase II study investigating oral metronomic vinorelbine versus conventional dosage of vinorelbine in HER2-negative metastatic breast cancer previously treated with anthracycline or taxane:clinical results and biomarker analysis. Cancer Research, 2022, 82, P1-16-02-P1-16-02.	0.9	0
171	Chemotherapy Decision-Making and Survival Outcomes in Older Women With Early Triple-Negative Breast Cancer: Evidence From Real-World Practice. Frontiers in Oncology, 2022, 12, 867583.	2.8	0
172	Analysis of non-sentinel lymph node status on 10-year overall survival among patients with breast cancer and sentinel lymph node metastasis.. Journal of Clinical Oncology, 2022, 40, e12584-e12584.	1.6	0
173	Genomic landscape and peripheral blood biomarkers of advanced triple-negative breast cancer treated with immune checkpoint blockade: An exploratory analysis of the TQB2450-1b-07 trial.. Journal of Clinical Oncology, 2022, 40, 1080-1080.	1.6	0
174	Abstract 5689: Effects of homologous recombination-related gene mutation subtypes on gene instability and the efficacy of platinum-containing regimens in triple-negative breast cancer. Cancer Research, 2022, 82, 5689-5689.	0.9	0
175	Abstract 5084: <i>KMT2D</i> and <i>PIK3CA</i> mutation as potential factors to predict adjuvant chemotherapy efficacy in surgical triple negative breast cancer. Cancer Research, 2022, 82, 5084-5084.	0.9	0
176	The efficacy and safety of apatinib combined with paclitaxel and carboplatin dose-dense regimen in neoadjuvant therapy for locally advanced triple-negative breast cancer.. Journal of Clinical Oncology, 2022, 40, e12602-e12602.	1.6	0
177	Analysis of prognostic factors and survival outcomes for patients with T1N0 HER2-positive infiltrating ductal carcinoma of the breast: A real-world study with long-term follow-up.. Journal of Clinical Oncology, 2022, 40, e12530-e12530.	1.6	0
178	Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR+/HER2- advanced breast cancer: A phase Ib study.. Journal of Clinical Oncology, 2022, 40, 1066-1066.	1.6	0
179	28-gene classifier model for prediction of local recurrence and distant metastasis risk in HER-2 positive operable breast cancer.. Journal of Clinical Oncology, 2022, 40, e13018-e13018.	1.6	0